检索范围:
排序: 展示方式:
《医学前沿(英文)》 2021年 第15卷 第6期 页码 942-942 doi: 10.1007/s11684-021-0876-z
null
《医学前沿(英文)》 2016年 第10卷 第1期 页码 41-51 doi: 10.1007/s11684-016-0429-z
Midline2 (MID2) is an ubiquitin-conjugating E2 enzyme linked to tumor progression and a novel interacting partner of breast cancer 1, early-onset (BRCA1). However, the role of MID2 in breast cancer remains unknown. This study investigated the expression, prognostic value, and role of MID2 in breast cancer. The expression of MID2 mRNA and protein was significantly upregulated in breast cancer tissue and established cell lines compared with that in normal breast epithelial cells and paired adjacent non-tumor tissue (P<0.001). Immunohistochemical analysis demonstrated that MID2 was overexpressed in 272 of 284 (95.8%) paraffin-embedded, archived breast cancer tissue. Moreover, MID2 expression increased with advanced clinical stage (P<0.001). High MID2 expression was significantly associated with advanced clinical stages and T, N, and M staging (all P<0.05). Univariate and multivariate analyses indicated that high MID2 expression was an independent prognostic factor for poor overall survival in the entire cohort (93.73 vs. 172.1 months; P<0.001, log-rank test) and in subgroups with stages Tis+ I+ II and III+ IV. Furthermore, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide colony formation, and anchorage-independent growth ability assays were conducted. Results showed that siRNA silencing of MID2 expression significantly reduced MCF-7 and MDA-MB-231 cell proliferation in vitro and blocked the growth of MDA-MB-231 cell xenograft tumors in vivo (P<0.05). This study indicated that MID2 may be a novel prognostic marker and interventional target in breast cancer.
关键词: breast cancer MID2 proliferation overall survival xenograft
Qiong DAI MD, Bei LIU MD, Yukai DU MM,
《医学前沿(英文)》 2009年 第3卷 第4期 页码 452-458 doi: 10.1007/s11684-009-0080-z
关键词: meta-analysis breast cancer risk factors reproductive factors oral contraceptive use
Metabolism and immunity in breast cancer
Deyu Zhang, Xiaojie Xu, Qinong Ye
《医学前沿(英文)》 2021年 第15卷 第2期 页码 178-207 doi: 10.1007/s11684-020-0793-6
A comprehensive information database (CID) of breast cancer patients in China
null
《医学前沿(英文)》 2012年 第6卷 第2期 页码 212-216 doi: 10.1007/s11684-012-0185-7
Jiayi Wu, Weiqi Gao, Xiaosong Chen, Chunxiao Fei, Lin Lin, Weiguo Chen, Ou Huang, Siji Zhu, Jianrong He, Yafen Li, Li Zhu, Kunwei Shen
《医学前沿(英文)》 2021年 第15卷 第4期 页码 621-628 doi: 10.1007/s11684-020-0738-0
关键词: early breast cancer 21-gene assay recurrence score prognosis
Jacqueline CONCHA, Caroline WEINSTEIN, María Elvira Zú?IGA
《化学科学与工程前沿(英文)》 2013年 第7卷 第4期 页码 482-489 doi: 10.1007/s11705-013-1342-5
关键词: pectic extracts antiproliferative activity breast cancer enzymatic treatment
null
《医学前沿(英文)》 2016年 第10卷 第1期 页码 33-40 doi: 10.1007/s11684-016-0431-5
Breast cancer is the most common malignant tumor in women, and the incidence of this disease has increased in recent years because of changes in diet, living environment, gestational age, and other unknown factors. Previous studies focused on cancer cells, but an increasing number of recent studies have analyzed the contribution of cancer microenvironment to the initiation and progression of breast cancer. Cancer-associated fibroblasts (CAFs), the most abundant cells in tumor stroma, secrete various active biomolecules, including extracellular matrix components, growth factors, cytokines, proteases, and hormones. CAFs not only facilitate the initiation, growth, angiogenesis, invasion, and metastasis of cancer but also serve as biomarkers in the clinical diagnosis, therapy, and prognosis of breast cancer. In this article, we reviewed the literature and summarized the research findings on CAFs in breast cancer.
关键词: cancer-associated fibroblast breast cancer progression prognosis
《医学前沿(英文)》 doi: 10.1007/s11684-023-1016-8
关键词: p53 mutation triple-negative breast cancer decitabine DNMT1 IRF7 innate immune response
Progress in systemic therapy for triple-negative breast cancer
Hongnan Mo, Binghe Xu
《医学前沿(英文)》 2021年 第15卷 第1期 页码 1-10 doi: 10.1007/s11684-020-0741-5
关键词: triple-negative breast cancer immunotherapy targeted therapy
Biosensor-based assay of exosome biomarker for early diagnosis of cancer
《医学前沿(英文)》 2022年 第16卷 第2期 页码 157-175 doi: 10.1007/s11684-021-0884-z
Soy food consumption in relation to breast cancer modified by menopause status
YANG Rong, ZHANG Bin, YANG Shaoping, ZHANG Dan, DU Yukai
《医学前沿(英文)》 2008年 第2卷 第4期 页码 348-351 doi: 10.1007/s11684-008-0066-2
How to judge the association of postmenopausal hormone therapy and the risk of breast cancer
Ling XU
《医学前沿(英文)》 2010年 第4卷 第3期 页码 290-293 doi: 10.1007/s11684-010-0093-7
关键词: breast cancer postmenopausal hormone therapy unopposed estrogen therapy combined estrogen-progestin therapy
Andrew Best,Katherine James,Gerald Hysenaj,Alison Tyson-Capper,David J. Elliott
《化学科学与工程前沿(英文)》 2016年 第10卷 第2期 页码 186-195 doi: 10.1007/s11705-015-1540-4
关键词: RNA splicing gene expression breast cancer DNA damage CHK1
Low-dose CT for lung cancer screening: opportunities and challenges
null
《医学前沿(英文)》 2018年 第12卷 第1期 页码 116-121 doi: 10.1007/s11684-017-0600-1
Lung cancer is among the most frequently diagnosed cancers worldwide and the leading cause of cancer death in both males and females. Screening for lung cancer coupled with earlier intervention has long been studied as an approach to mortality reduction. However, minimal progress was achieved until recently, when low-dose spiral computed tomography (LDCT) screening demonstrated a 20% reduction in mortality from lung cancer in a randomized controlled trial (RCT), the National Lung Screening Trial, from the United States. On the basis of this finding, LDCT has been recommended for lung cancer screening in high-risk populations by several clinical guidelines. However, results from the following independent RCTs in Europe failed to show consistent conclusions. In addition, intractable problems gradually emerged with the progress of LDCT screening. This paper summarizes and discusses the main observations and challenges of LDCT screening for lung cancer. Before spreading implementation of LDCT screening, challenges, including high false-positive rates, overdiagnosis, enormous costs, and radiation risk, must be addressed. Complementary biomarkers and technical improvement are expected in the field of lung cancer screening in the near future.
关键词: lung cancer low-dose computerized tomography early detection opportunities challenges
标题 作者 时间 类型 操作
Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer
期刊论文
Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer
null
期刊论文
Meta-analysis of the risk factors of breast cancer concerning reproductive factors and oral contraceptive
Qiong DAI MD, Bei LIU MD, Yukai DU MM,
期刊论文
Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breastcancer was similar in node-negative diseases: a single-center study of 800 patients
Jiayi Wu, Weiqi Gao, Xiaosong Chen, Chunxiao Fei, Lin Lin, Weiguo Chen, Ou Huang, Siji Zhu, Jianrong He, Yafen Li, Li Zhu, Kunwei Shen
期刊论文
Production of pectic extracts from sugar beet pulp with antiproliferative activity on a breast cancer
Jacqueline CONCHA, Caroline WEINSTEIN, María Elvira Zú?IGA
期刊论文
Breast cancer-associated fibroblasts: their roles in tumor initiation, progression and clinical applications
null
期刊论文
Decitabine induces -mediated immune responses in p53-mutated triple-negative breast cancer: a clinical
期刊论文
Soy food consumption in relation to breast cancer modified by menopause status
YANG Rong, ZHANG Bin, YANG Shaoping, ZHANG Dan, DU Yukai
期刊论文
How to judge the association of postmenopausal hormone therapy and the risk of breast cancer
Ling XU
期刊论文
Transformer2 proteins protect breast cancer cells from accumulating replication stress by ensuring productive
Andrew Best,Katherine James,Gerald Hysenaj,Alison Tyson-Capper,David J. Elliott
期刊论文